New Parkinson's Treatment Shows Promise in Animals
... controlled using the medication levodopa, When combined with another drug, levodopa
is converted into dopamine in the brain.
But as the disease progresses, the benefits from levodopa
Patients with Parkinson's who are no longer responding wel...
Parkinson's Treatment Drugs Even Out Over Long Term
... Levels of disability, quality of life similar on levodopa
or pramipexole, study finds
WEDNESDAY, March 11 (HealthDay News) -- Two drugs -- levodopa
and pramipexole -- used to treat early stage Parki...ne in the brain that causes Parkinson's symptoms. levodopa
is an amino acid that the body metabolizes into do...
Family History of Melanoma Doubles Parkinson's Risk
...found that Parkinson's patients taking levodopa, a common treatment for the condition, were more susceptible to melanoma, Gao said. "They thought that levodopa
increased the risk of melanoma," he explained.
But later reports found that people with melanoma were at high risk of developing Parkinson's diseas...
Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Sinemet(R) Tablets
...nnounced today, that it has launched
Carbidopa and levodopa
tablets on behalf of Sun Pharmaceutical Industries...A) for generic Sinemet(R) tablets.
Carbidopa and levodopa
tablets are used in the treatment of Parkinson's
d... syndrome. These generic versions of Carbidopa and levodopa
mg / 100 mg, 25 mg / 100 mg, and 25 mg / 250 mg...
New Hope for Parkinson's Patients
In the second study, a patch delivery system for levodopa
also appeared to ease motor problems in Parkinson'...nts.
The study compared healthy volunteers on a levodopa
patch against those taking carbidopa orally every ...onstant therapeutic delivery of medication.
can be administered in a way to bypass the gastroi...
Drug May Cut Tremors Associated With Parkinson's
... popular Parkinson's drug, found those using istradefylline experienced 24 percent less "off" time, defined as when the physical symptoms appear after levodopa
wears off. A group of those studied who took a placebo showed a 10 percent decrease in "off" time.
"These results suggest that istradefylline is ef...
Eye Cell Implants Improve Parkinson's Symptoms
... eye cells naturally begin to produce levodopa. The researchers believe the levodopa
is then turned into dopamine, a neurotransmitter lacking in people with Par...atients selected for the study were chosen based on their responsiveness to levodopa
and the severity of their symptoms when they were off their medication. Us...
'Proud Hands' Book Released to Benefit the American Parkinson Disease Association
...oms of Parkinson's disease both as initial therapy alone and
to be added to levodopa
later in the disease. The effectiveness of AZILECT
was shown in patients wi...AZILECT alone are headache, joint pain and
indigestion; and when taken with levodopa
are uncontrolled movements
(dyskinesias), accidental injury, nausea, weight...
Neupro(R) Filed with the FDA for the Treatment of Restless Legs Syndrome
...) is indicated for the treatment of the signs
and symptoms of early-stage idiopathic Parkinson's disease as monotherapy
and as adjunctive therapy with levodopa
in advanced-stage Parkinson's
About Restless Legs Syndrome:
Restless legs syndrome (RLS) is a chronic neurological disorder that
Neupro(R) Filed with the FDA for the Treatment of Advanced-Stage Parkinson's Disease
...ine Transdermal System) as adjunctive therapy with levodopa
in adult patients with advanced-stage Park...or the use of Neupro(R) as
adjunctive therapy with levodopa
in adult patients with advanced-stage
Parkinson's ...nstrated that rotigotine, as adjunctive therapy to levodopa
with advanced-stage Parkinson's diseas...
Levodopa in Medical Technology
Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels
WELLESLEY HILLS, Mass., Aug. 25 /PRNewswire/ -- Joseph F. Finn, Jr.,
C.P.A. ("Finn"), Assignee of the assets of Spherics, Inc. ("Spherics") for
the benefit of creditors, announced today that all pharmaceutical
intellectual property will be sold at a sealed bid auction on October 10,
Once Daily, Extended-Release Ropinirole Improves Parkinson's
Symptoms in Patients not Optimally Controlled With Levodopa
'Off' Time Reduced By an Average of More Than Two Hours Per Day
RESEARCH TRIANGLE PARK, N.C., April 02, 2007 /PRNewswire/ --
Adding the once daily, investigational medication REQUIP(R)
(ropinirole HCl) XL 24-Hour(TM) Extended-Release Tablets to
Parkinson's patients' existing levodopa
Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial
...es of a dopamine agonist and/or
an anti-cholinergic drug. After a four-week levodopa
phase, study participants were randomized to one of th...r matching placebo
tablets (222 patients), as adjunctive treatment to their levodopa
primary efficacy endpoint of the study was the increase in mea...
Kyowa Hakko Kirin Announces Development Policy for Anti-Parkinson's Disease Drug KW-6002 (Istradefylline)
...phenomenon*, a motor complication, while receiving levodopa
therapy alone or in combination with other anti-Pa...ted primarily by dopamine replacement therapy with levodopa
or dopamine agonists. Long term therapy with levodopa
is associated with motor complications such as the...
Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics
levodopa, which could lessen debilitating side effects of the drug
including dyskinesias, the uncontrollable movements that arise with
therapy (Verne Cowles, Ph.D., and S. Y. Eddie Hou,
Ph.D., Depomed, Inc., Menlo Park, California);
-- Validating a novel metabolomic diagnostic test ...
Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinson's Disease
...She will use the model to test drugs
that can alleviate this 'non-motor' symptom, which might also allow for
better delivery of existing drugs such as levodopa
that must pass through
the GI tract to enter the bloodstream.
A complete list of researchers who were awarded grants under Target
Validation 2007, i...
U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease
... Requip XL Improved Symptoms in Patients Not Optimally Controlled with
and Reduced Patients' "Off" Time by Nearly Two Hours Per Day
RESEARCH TRI...fficacy and safety trial showed
that adding Requip XL to patients' existing levodopa
reduced the amount of "off" time experienced by patients w...
Status of the E2007 (perampanel) Development Program
and 309) with perampanel as add-on therapy to levodopa
in patients with
late-stage disease. Additionally,...oms of Parkinson's disease return as the effect of levodopa
off). Perampanel was generally well tolerate... different from that of
dopaminergic drugs such as levodopa
and dopamine agonists, in-depth review
will be nec...
Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
...ncluding strategies to
alleviate complications of current treatments such as dyskinesias (the
disruptive movements that are a side effect of long-term levodopa
Foundation is also eager to support development of treatments that address
'non-motor' aspects of PD, such as cognitive dysfunction, depressi...
BioMarin Announces FDA Approval for Kuvan
...e conditions should be carefully monitored when
receiving Kuvan. Caution should be used with the administration of Kuvan to
patients who are receiving levodopa
and drugs that affect nitric
oxide-mediated vasorelaxation or folate metabolism.
The most serious adverse reactions reported during Kuvan administra...
Levodopa in Biological News
Levodopa in Biological Technology
Clinical Pharmacology Study With AZILECT(R) (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity
...f Parkinson's disease (PD) both as initial therapy alone and to be added to levodopa
later in the disease.
IMPORTANT SAFETY INFORMATION ABOUT AZILECT
...ZILECT alone are headache, joint pain, and indigestion; and when taken with levodopa
are uncontrolled movements (dyskinesias), accidental injury, nausea, weight...
New Report Provides Expert Analysis of Recent Advances and Setbacks in Parkinson's Disease Drug Development
... neurturin, neublastin, GAD/glutamic acid decarboxylase),
-- Dopamine agonists, monoamine oxidase inhibitors;
formulations, COMT inhibitors; and
-- Adenosine A2A receptor antagonists, cholinesterase inhibitors, AMPA,
5-HT, anticonvulsants, antihyper...